Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 10

1.

Impact of age on the use of adjuvant treatments in patients undergoing surgery for colorectal cancer: patients with stage III colon or stage II/III rectal cancer.

Sarasqueta C, Perales A, Escobar A, Baré M, Redondo M, Fernández de Larrea N, Briones E, Piera JM, Zunzunegui MV, Quintana JM; REDISECC-CARESS/CCR group.

BMC Cancer. 2019 Jul 25;19(1):735. doi: 10.1186/s12885-019-5910-z.

2.

Wnt-11 as a Potential Prognostic Biomarker and Therapeutic Target in Colorectal Cancer.

Gorroño-Etxebarria I, Aguirre U, Sanchez S, González N, Escobar A, Zabalza I, Quintana JM, Vivanco MD, Waxman J, Kypta RM.

Cancers (Basel). 2019 Jun 28;11(7). pii: E908. doi: 10.3390/cancers11070908.

3.

Imaging Mass Spectrometry-Based Lipidomic Approach to Classification of Architectural Features in Nevi.

Garate J, Lage S, Fernández R, Velasco V, Abad B, Asumendi A, Gardeazabal J, Arroyo-Berdugo Y, Rodríguez MÁ, Artola JL, Zabalza I, Ochoa B, Fernández JA, Boyano MD.

J Invest Dermatol. 2019 Mar 13. pii: S0022-202X(19)31323-5. doi: 10.1016/j.jid.2019.01.031. [Epub ahead of print] No abstract available.

PMID:
30878679
4.

A Sox2-Sox9 signalling axis maintains human breast luminal progenitor and breast cancer stem cells.

Domenici G, Aurrekoetxea-Rodríguez I, Simões BM, Rábano M, Lee SY, Millán JS, Comaills V, Oliemuller E, López-Ruiz JA, Zabalza I, Howard BA, Kypta RM, Vivanco MD.

Oncogene. 2019 Apr;38(17):3151-3169. doi: 10.1038/s41388-018-0656-7. Epub 2019 Jan 8.

5.

In Silico Approach for Immunohistochemical Evaluation of a Cytoplasmic Marker in Breast Cancer.

Mazo C, Orue-Etxebarria E, Zabalza I, Vivanco MDM, Kypta RM, Beristain A.

Cancers (Basel). 2018 Dec 15;10(12). pii: E517. doi: 10.3390/cancers10120517.

6.

Protective effect of stromal Dickkopf-3 in prostate cancer: opposing roles for TGFBI and ECM-1.

Al Shareef Z, Kardooni H, Murillo-Garzón V, Domenici G, Stylianakis E, Steel JH, Rabano M, Gorroño-Etxebarria I, Zabalza I, Vivanco MD, Waxman J, Kypta RM.

Oncogene. 2018 Sep;37(39):5305-5324. doi: 10.1038/s41388-018-0294-0. Epub 2018 Jun 1.

7.

Mutational profiling can identify laryngeal dysplasia at risk of progression to invasive carcinoma.

Manterola L, Aguirre P, Larrea E, Arestín M, Gaafar A, Elorriaga K, Goicoechea I, Armesto M, Fernández-Mercado M, Zabalza I, López-Duque JC, Larruskain E, Sistiaga JA, Landa M, Zabala A, Santaolalla F, Municio JA, Ispizua Á, García-Pedrero JM, Rodrigo JP, Lawrie CH.

Sci Rep. 2018 Apr 26;8(1):6613. doi: 10.1038/s41598-018-24780-7.

8.

Colorectal cancer health services research study protocol: the CCR-CARESS observational prospective cohort project.

Quintana JM, Gonzalez N, Anton-Ladislao A, Redondo M, Bare M, Fernandez de Larrea N, Briones E, Escobar A, Sarasqueta C, Garcia-Gutierrez S, Aguirre U; REDISSEC-CARESS/CCR group.

BMC Cancer. 2016 Jul 8;16:435. doi: 10.1186/s12885-016-2475-y.

9.

Distinct breast cancer stem/progenitor cell populations require either HIF1α or loss of PHD3 to expand under hypoxic conditions.

Iriondo O, Rábano M, Domenici G, Carlevaris O, López-Ruiz JA, Zabalza I, Berra E, Vivanco Md.

Oncotarget. 2015 Oct 13;6(31):31721-39. doi: 10.18632/oncotarget.5564.

10.

Sox2 promotes tamoxifen resistance in breast cancer cells.

Piva M, Domenici G, Iriondo O, Rábano M, Simões BM, Comaills V, Barredo I, López-Ruiz JA, Zabalza I, Kypta R, Vivanco Md.

EMBO Mol Med. 2014 Jan;6(1):66-79.

Supplemental Content

Loading ...
Support Center